Release Date: September 10, 2018 Expiration Date: September 30, 2019 (subject to change)
CE for this activity will not be available after this date.
Overview Two expert faculty and a patient with diabetes interact to bring current guideline recommendations for reaching glycemic control and reducing cardiovascular risk in patients with type 2 diabetes mellitus (T2DM). This unique format will help participants identify and assist their patents to recognize and overcome barriers to optimal blood sugar control and clinical inertia in diabetes care.
This CE activity is a recording of a CE session from the AANP 2018 National Conference. It has been edited to meet the format requirements for online learning. If you received CE credit for attending the live session at Conference, you many not receive duplicate credit for this same activity in a different format. CE Credit Instructions
Read this activity description, including objectives and disclosures.
Complete the educational content completely:
Video Presentations: Watch all video presentations completely.
Review all additional materials provided (handouts, posttest reviews, any other downloadable resources).
After completing all content, go to Steps to Receive Credit to complete the posttest and evaluation to receive full AANP CE/Rx credit. If other types of credit are offered, these options will be available after completing the activity evaluation.
Correctly apply guideline recommendations for evidence-based care for patients with T2DM to reduce CVD risk and adverse events
Summarize recent clinical trial data on new pharmacotherapies that combine glucose-lowering benefit with cardio-protection in at-risk patents with T2DM
Appropriately select the best treatment individualized to specific patient populations base on the medication profiles of SGLT2 inhibitors and GLP-1 RAs
Faculty Dixie Harms, DNP, ARNP, FNP-C, BC-ADM, FAANP Davida Kruger MSN, APN-BC, BC-ADM Mark-John Clifford-patient advocate Disclosure This activity was planned in accordance with AANP Accreditation Standards and Policies. This activity sponsored by an educational grant from BI/Eli Lilly and Novo Nordisk. Dr. Harms discloses the following affiliations: Adjunct Clinical Faculty University of Iowa College of Nursing, Speakers’ bureaus: Sanofi Aventis, Novo Nordisk, Intarcia. Davida Kruger discloses the following affiliations: Speakers’ Bureau: BI, Lilly, Janssen, AstraZeneca. Mark-John Clifford has no relevant affiliations to disclose.
This educational activity may contain opinions of the speakers from their personal experience. The activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program. Additional Information For questions about this online CE activity, or more information concerning the AANP CE Center, contact the AANP CE Center Manager at CECenter@aanp.org.
1 Contact Hour(s) of CE, All of which may be applied towards Pharmacology
Additional CE activities of interest
(OnDemand) Starting & Adjusting Insulin in Type 2 Diabetes in Primary Care
(OnDemand) What’s New in Oral Medications for T2DM?
(OnDemand) Untying the Shoe, Management of the Diabetic Foot
(OnDemand) Improving Care and Outcomes in Type 2 Diabetes: A Nurse Practitioner-Led Charge for Overcoming Insulin Inertia
(Publication ) Managing the Diabetic Kidney Patient
(OnDemand) Managing Diabetes Through Acute & Concurrent Illness
(OnDemand) Useful Tools for Promoting Behavior Change and Self-Management in Diabetes and Prediabetes